Appropriations legislation related to FDA and compounding pharmacy.
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Legislation relating to regulation of compounding pharmacies.
Duration: April 16, 2013
to
present
General Issues: Budget/Appropriations , Health Issues , Pharmacy , Law Enforcement/Crime/Criminal Justice , Medical/Disease Research/Clinical Labs
Spending: about $493,075 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives, Food & Drug Administration (FDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
James Rock
Staff Asst, US House Committee on Budget - 1985 to 2000
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
Rock & Associates amended a lobbying report for representation of Braidwood Management, Inc. in Q12024 on May 8.
Original Filing: 301578942.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2024
Rock & Associates amended a lobbying report for representation of Braidwood Management, Inc. in Q12024 on May 8.
Original Filing: 301578945.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2024
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 24.
Original Filing: 301577095.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2023
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 24.
Original Filing: 301577091.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2023
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on March 18.
Original Filing: 301545317.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2023
Rock & Associates amended a lobbying report for representation of Braidwood Management, Inc. in Q32023 on March 18.
Original Filing: 301545318.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2023
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Sept. 8, 2023.
Original Filing: 301496131.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2023
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on May 11, 2023.
Original Filing: 301470865.xml
Lobbying Issues
Appropriations legislation related to FDA and compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation relating to regulation of compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2022
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on March 2, 2023.
Original Filing: 301447509.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2022
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Nov. 8, 2022.
Original Filing: 301422359.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2022
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Aug. 6, 2022.
Original Filing: 301398291.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2022
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on June 24, 2022.
Original Filing: 301376714.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2021
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Feb. 15, 2022.
Original Filing: 301341410.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2021
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 31, 2021.
Original Filing: 301316677.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2021
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Aug. 11, 2021.
Original Filing: 301294248.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2021
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on May 4, 2021.
Original Filing: 301270338.xml
Lobbying Issues
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2020
Rock & Associates amended a lobbying report for representation of Braidwood Management, Inc. in Q42020 on Feb. 9, 2021.
Original Filing: 301248010.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2020
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 29, 2021.
Original Filing: 301247200.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2020
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 14, 2020.
Original Filing: 301210078.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2020
Rock & Associates amended a lobbying report for representation of Braidwood Management, Inc. in Q22020 on Aug. 26, 2020.
Original Filing: 301205844.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2020
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Aug. 1, 2020.
Original Filing: 301204387.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2020
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on June 6, 2020.
Original Filing: 301184233.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2019
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 25, 2020.
Original Filing: 301130446.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2019
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 19, 2019.
Original Filing: 301072175.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2019
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on July 17, 2019.
Original Filing: 301048170.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2019
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 18, 2019.
Original Filing: 301029548.xml
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
4th Quarter, 2018
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 17, 2019.
Original Filing: 301006611.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
3rd Quarter, 2018
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 14, 2018.
Original Filing: 300985068.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
2nd Quarter, 2018
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on July 18, 2018.
Original Filing: 300968442.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2018
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 19, 2018.
Original Filing: 300951915.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 17, 2018.
Original Filing: 300925196.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 18, 2017.
Original Filing: 300906911.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on July 15, 2017.
Original Filing: 300885201.xml
Lobbying Issues
Appropriations for FDA for FY2017 and FY2018. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting compounding pharmacy. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to controlled substances and pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 17, 2017.
Original Filing: 300865991.xml
Lobbying Issues
Appropriations for FDA for FY2017 and FY2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting compounding pharmacy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to controlled substances and pharmacy compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues pertaining to pharmacy compounding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 13, 2017.
Original Filing: 300845836.xml
Lobbying Issues
Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 11, 2016.
Original Filing: 300826234.xml
Lobbying Issues
Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on July 8, 2016.
Original Filing: 300807553.xml
Lobbying Issues
Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 12, 2016.
Original Filing: 300790056.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2015
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 11, 2016.
Original Filing: 300770389.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2015
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 13, 2015.
Original Filing: 300752239.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2015
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on July 13, 2015.
Original Filing: 300733575.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2015
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 7, 2015.
Original Filing: 300712966.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2014
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 13, 2015.
Original Filing: 300694651.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations. H.R. 4800 and S. 2437.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of dispense to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2014
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Oct. 9, 2014.
Original Filing: 300674815.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations. H.R. 4800 and S.2437.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2014
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on July 10, 2014.
Original Filing: 300654940.xml
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations.
H.R. 4800 and S. 2437.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislation affecting the operation compounding pharmacies and the availability of compounded medications. No specific legislation yet.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2014
In Q1, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on April 15, 2014.
Original Filing: 300635747.xml
Lobbying Issues
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Appropriations to fund the FDA implementation of compounding pharmacy regulations. No specific legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,250. The report was filed on Jan. 13, 2014.
Original Filing: 300613142.xml
Lobbying Issues
S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medical/Disease Research/Clinical Labs Pharmacy
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2013
In Q3, Rock & Associates lobbied for Braidwood Management, Inc. , earning $11,200. The report was filed on Oct. 8, 2013.
Original Filing: 300591413.xml
Lobbying Issues
S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medical/Disease Research/Clinical Labs Pharmacy
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2013
In Q2, Rock & Associates lobbied for Braidwood Management, Inc. , earning $9,375. The report was filed on July 15, 2013.
Original Filing: 300572390.xml
Lobbying Issues
S.959, legislation affecting the operation of compounding pharmacies and the availability of compounded medications.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medical/Disease Research/Clinical Labs Pharmacy
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2013
Rock & Associates filed a lobbying registration on May 14, 2013 to represent Braidwood Management, Inc., effective April 16, 2013.
Original Filing: 300567423.xml
Issue(s) they said they’d lobby about: Issues related to the operation of compounding pharmacies and the availability of compounded medications. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate